Literature DB >> 25187603

Epidemiology and clinical features of toxigenic culture-confirmed hospital-onset Clostridium difficile infection: a multicentre prospective study in tertiary hospitals of South Korea.

Sang Hoon Han1, Heejung Kim2, Kyungwon Lee2, Su Jin Jeong1, Ki-Ho Park3, Joon Young Song4, Yu Bin Seo4, Jun Yong Choi1, Jun Hee Woo3, Woo Joo Kim4, June Myung Kim1.   

Abstract

Hypervirulent Clostridium difficile strains, most notably BI/NAP1/027, have been increasingly emerging in Western countries as local epidemics. We performed a prospective multicentre observational study from December 2011 to May 2012 to identify recent incidences of toxigenic culture-confirmed hospital-onset C. difficile infections (CDI) and their associated clinical characteristics in South Korea. Patients suspected of having been suffering from CDI more than 48 h after admission and aged ≥20 years were prospectively enrolled and provided loose stool specimens. Toxigenic C. difficile culture (anaerobic culture+toxin A/B/binary gene PCR) and PCR ribotyping were performed in one central laboratory. We enrolled 98 toxigenic culture-confirmed CDI-infected patients and 250 toxigenic culture-negative participants from three hospitals. The incidence of toxigenic culture-confirmed hospital-onset CDI cases was 2.7 per 10,000 patient-days. The percentage of severe CDI cases was relatively low at only 3.1%. UK ribotype 018 was the predominant type (48.1%). There were no hypervirulent BI/NAP1/027 isolates identified. The independent risk factors for toxigenic culture-confirmed hospital-onset CDI were invasive procedure (odds ratio (OR) 7.3, P=0.003) and past CDI history within 3 months (OR 28.5, P=0.003). In conclusion, the incidence and severity of CDI in our study were not higher than reported in Western countries.
© 2014 The Authors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25187603     DOI: 10.1099/jmm.0.070672-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Clostridium difficile PCR Ribotype 018, a Successful Epidemic Genotype.

Authors:  Rossella Baldan; Alberto Trovato; Valentina Bianchini; Anna Biancardi; Paola Cichero; Maria Mazzotti; Paola Nizzero; Matteo Moro; Cristina Ossi; Paolo Scarpellini; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

Review 2.  Clostridium difficile Infection: An Epidemiology Update.

Authors:  Ana C De Roo; Scott E Regenbogen
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

3.  Draft Genome Sequence of Clostridium difficile Belonging to Ribotype 018 and Sequence Type 17.

Authors:  E Riccobono; V Di Pilato; N Della Malva; S Meini; F Ciraolo; F Torricelli; G M Rossolini
Journal:  Genome Announc       Date:  2016-09-01

4.  Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolates from two Korean hospitals.

Authors:  Asiimwe Nicholas; Yu Kyung Kim; Won-Kil Lee; Gati Noble Selasi; Seok Hyeon Na; Hyo Il Kwon; Yoo Jeong Kim; Hae Sook Lee; Kyung Eun Song; Jeong Hwan Shin; Je Chul Lee
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

5.  New Insights into Clostridium difficile (CD) Infection in Latin America: Novel Description of Toxigenic Profiles of Diarrhea-Associated to CD in Bogotá, Colombia.

Authors:  Marina Muñoz; Dora I Ríos-Chaparro; Giovanny Herrera; Sara C Soto-De Leon; Claudia Birchenall; Darío Pinilla; Juan M Pardo-Oviedo; Diego F Josa; Manuel A Patarroyo; Juan D Ramírez
Journal:  Front Microbiol       Date:  2018-01-30       Impact factor: 5.640

6.  Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea.

Authors:  Dae Bum Kim; Kang-Moon Lee; Sang Hyoung Park; You Sun Kim; Eun Soo Kim; Jun Lee; Sung-Ae Jung; Geom Seog Seo; Ji Min Lee
Journal:  Intest Res       Date:  2018-04-30

7.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.